Literature DB >> 30381416

Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply.

Richard M Stone1, Coleman Lindsley2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30381416      PMCID： PMC6278980          DOI： 10.3324/haematol.2018.201848

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

2.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

Review 3.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Authors:  Guido Marcucci; Torsten Haferlach; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Authors:  R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert
Journal:  Blood       Date:  2014-12-30       Impact factor: 22.113

5.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

Authors:  C P Leith; K J Kopecky; J Godwin; T McConnell; M L Slovak; I M Chen; D R Head; F R Appelbaum; C L Willman
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

Review 6.  How I treat the older patient with acute myeloid leukemia.

Authors:  Gert Ossenkoppele; Bob Löwenberg
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

7.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Authors:  Klaus H Metzeler; Tobias Herold; Maja Rothenberg-Thurley; Susanne Amler; Maria C Sauerland; Dennis Görlich; Stephanie Schneider; Nikola P Konstandin; Annika Dufour; Kathrin Bräundl; Bianka Ksienzyk; Evelyn Zellmeier; Luise Hartmann; Philipp A Greif; Michael Fiegl; Marion Subklewe; Stefan K Bohlander; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann; Jan Braess; Karsten Spiekermann
Journal:  Blood       Date:  2016-06-10       Impact factor: 22.113

8.  Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

Authors:  Courtney D DiNardo; Eytan M Stein; Stéphane de Botton; Gail J Roboz; Jessica K Altman; Alice S Mims; Ronan Swords; Robert H Collins; Gabriel N Mannis; Daniel A Pollyea; Will Donnellan; Amir T Fathi; Arnaud Pigneux; Harry P Erba; Gabrielle T Prince; Anthony S Stein; Geoffrey L Uy; James M Foran; Elie Traer; Robert K Stuart; Martha L Arellano; James L Slack; Mikkael A Sekeres; Christophe Willekens; Sung Choe; Hongfang Wang; Vickie Zhang; Katharine E Yen; Stephanie M Kapsalis; Hua Yang; David Dai; Bin Fan; Meredith Goldwasser; Hua Liu; Sam Agresta; Bin Wu; Eyal C Attar; Martin S Tallman; Richard M Stone; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2018-06-02       Impact factor: 91.245

9.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

10.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717
View more
  2 in total

1.  Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry.

Authors:  Kwai Han Yoo; Hyeoung-Joon Kim; Yoo Hong Min; Dae-Sik Hong; Won Sik Lee; Hee-Je Kim; Ho-Jin Shin; Yong Park; Je-Hwan Lee; Hawk Kim
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

2.  Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation.

Authors:  H Joachim Deeg
Journal:  Blood Adv       Date:  2022-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.